NO20092455L - Modulering av prostaglandin/syklooksygenase-metabolske baner - Google Patents
Modulering av prostaglandin/syklooksygenase-metabolske banerInfo
- Publication number
- NO20092455L NO20092455L NO20092455A NO20092455A NO20092455L NO 20092455 L NO20092455 L NO 20092455L NO 20092455 A NO20092455 A NO 20092455A NO 20092455 A NO20092455 A NO 20092455A NO 20092455 L NO20092455 L NO 20092455L
- Authority
- NO
- Norway
- Prior art keywords
- metabolic pathways
- cyclooxygenase
- prostaglandin
- modulation
- inflammation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
Abstract
En rekke forskjellige sykdommer og forstyrrelser som er forbundet med de metabolske reaksjonsveiene som inngår i aktiviteten av syklooksygenase og syntesen av prostaglandiner, f.eks. type 2 diabetes mellitus og følgene av denne, iskemiske karsykdommer, smerte forbundet med betennelse, betennelsestilstander i huden, ryggmargsskade, perifer nevropati, multippel sklerose, inflammatorisk tarmsykdom og reumatoid artritt, så vel som forskjellige typer av kreft kan behandles eller forebygges ved anvendelse av et middel som selektivt fremmer dannelsen av 15deoksyprostaglandin J2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86787306P | 2006-11-30 | 2006-11-30 | |
GB0623971A GB0623971D0 (en) | 2006-11-30 | 2006-11-30 | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
PCT/GB2007/004584 WO2008065408A2 (en) | 2006-11-30 | 2007-11-29 | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20092455L true NO20092455L (no) | 2009-08-14 |
Family
ID=39381924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092455A NO20092455L (no) | 2006-11-30 | 2009-06-29 | Modulering av prostaglandin/syklooksygenase-metabolske baner |
Country Status (14)
Country | Link |
---|---|
US (2) | US20100137270A1 (no) |
EP (2) | EP2147673A1 (no) |
JP (1) | JP2010511028A (no) |
KR (1) | KR20090086272A (no) |
AU (1) | AU2007327011A1 (no) |
CA (1) | CA2670957A1 (no) |
HR (1) | HRP20120687T1 (no) |
IL (1) | IL199013A0 (no) |
MX (1) | MX2009005753A (no) |
NO (1) | NO20092455L (no) |
PL (1) | PL2097079T3 (no) |
TW (1) | TWI414298B (no) |
WO (1) | WO2008065408A2 (no) |
ZA (1) | ZA200903584B (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
GB0523550D0 (en) | 2005-11-18 | 2005-12-28 | Hunter Fleming Ltd | Therapeutic uses of steroidal compounds |
WO2013120851A1 (en) * | 2012-02-13 | 2013-08-22 | Mach-3D Sàrl | Method for sharing emotions through the creation of three-dimensional avatars and their interaction through a cloud-based platform |
US9328060B2 (en) | 2013-10-18 | 2016-05-03 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics |
JP6917631B2 (ja) * | 2016-02-15 | 2021-08-11 | 学校法人近畿大学 | 抗不安作用を有する医薬組成物および加工食品 |
WO2023060107A1 (en) * | 2021-10-05 | 2023-04-13 | University Of South Florida | Compositions and uses thereof for treatment of neurological disorders |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7100213A (en) * | 1971-01-08 | 1972-07-11 | 1,2,3,4-tetrahydrocarbazole derivs - anti-inflammatories | |
FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
US5451600A (en) * | 1994-04-19 | 1995-09-19 | Hoffmann-La Roche Inc. | Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors |
JP3258027B2 (ja) * | 1996-03-15 | 2002-02-18 | サマーセット・ファーマシューティカルズ・インコーポレイテッド | セレジリン投与による末梢ニューロパシーの予防および治療方法 |
WO2000006560A1 (en) * | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
GB0003524D0 (en) * | 2000-02-15 | 2000-04-05 | Btg Int Ltd | Cytoprotective steroids (II) |
GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
GB2363984A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
WO2002015791A2 (en) | 2000-08-25 | 2002-02-28 | Michael John Till | Sampling device |
EP2135611A1 (en) * | 2001-03-01 | 2009-12-23 | Hollis-Eden Pharmaceuticals Inc. | Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy |
SE0100857D0 (sv) * | 2001-03-13 | 2001-03-13 | Tomas Hagstroem | Treatment of tumors |
GB2378898A (en) | 2001-08-14 | 2003-02-26 | Hunter Fleming Ltd | Prophylactic and therapeutic use of hydroxysteroids |
FR2829697B1 (fr) * | 2001-09-14 | 2004-03-19 | Mayoly Spindler Lab | Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin |
GB0403889D0 (en) * | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
US20070231373A1 (en) * | 2004-04-28 | 2007-10-04 | Hunter-Fleming Limited | Transdermal Steriod for Formulation |
GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
US20060234993A1 (en) * | 2005-04-13 | 2006-10-19 | Eric Marchewitz | Use of androstane derivatives for enhancing physical performance |
-
2007
- 2007-11-29 KR KR1020097013708A patent/KR20090086272A/ko not_active Application Discontinuation
- 2007-11-29 US US12/516,772 patent/US20100137270A1/en not_active Abandoned
- 2007-11-29 AU AU2007327011A patent/AU2007327011A1/en not_active Abandoned
- 2007-11-29 EP EP09012181A patent/EP2147673A1/en not_active Withdrawn
- 2007-11-29 PL PL07870407T patent/PL2097079T3/pl unknown
- 2007-11-29 JP JP2009538785A patent/JP2010511028A/ja active Pending
- 2007-11-29 EP EP07870407A patent/EP2097079B1/en active Active
- 2007-11-29 CA CA002670957A patent/CA2670957A1/en not_active Abandoned
- 2007-11-29 WO PCT/GB2007/004584 patent/WO2008065408A2/en active Application Filing
- 2007-11-29 MX MX2009005753A patent/MX2009005753A/es active IP Right Grant
- 2007-11-30 TW TW096145663A patent/TWI414298B/zh not_active IP Right Cessation
-
2009
- 2009-05-22 ZA ZA2009/03584A patent/ZA200903584B/en unknown
- 2009-05-27 IL IL199013A patent/IL199013A0/en unknown
- 2009-06-29 NO NO20092455A patent/NO20092455L/no not_active Application Discontinuation
-
2012
- 2012-08-03 US US13/566,136 patent/US20130023504A1/en not_active Abandoned
- 2012-08-29 HR HRP20120687TT patent/HRP20120687T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008065408A9 (en) | 2011-03-03 |
WO2008065408A2 (en) | 2008-06-05 |
KR20090086272A (ko) | 2009-08-11 |
MX2009005753A (es) | 2009-09-28 |
WO2008065408A3 (en) | 2008-11-20 |
US20130023504A1 (en) | 2013-01-24 |
EP2097079A2 (en) | 2009-09-09 |
ZA200903584B (en) | 2010-11-24 |
TWI414298B (zh) | 2013-11-11 |
CA2670957A1 (en) | 2008-06-05 |
EP2097079B1 (en) | 2012-06-27 |
EP2147673A1 (en) | 2010-01-27 |
US20100137270A1 (en) | 2010-06-03 |
IL199013A0 (en) | 2010-02-17 |
JP2010511028A (ja) | 2010-04-08 |
HRP20120687T1 (hr) | 2012-09-30 |
TW200831108A (en) | 2008-08-01 |
AU2007327011A1 (en) | 2008-06-05 |
PL2097079T3 (pl) | 2012-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20092455L (no) | Modulering av prostaglandin/syklooksygenase-metabolske baner | |
EA201000321A1 (ru) | Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола | |
EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
WO2010049678A3 (en) | Treatment of energy utilization diseases | |
MY149316A (en) | Sirtuin modulating imidazohiazole compounds | |
ATE539748T1 (de) | Glucokinaseaktivatoren | |
WO2007102861A3 (en) | Modulators of cdc2-like kinases (clks) and methods of use thereof | |
EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
EA200802204A1 (ru) | Применение ингибиторов dpp iv | |
EA201101189A1 (ru) | Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии | |
EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
WO2008156869A3 (en) | Sirtuin modulating thiazolopyridine compounds | |
DE602007008042D1 (de) | Waschdesinfektor mit Bad, an das die Ablage mit daran befestigtem Endoskop abnehmbar geladen ist | |
EA201200975A1 (ru) | Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение | |
CL2004000639A1 (es) | Compuestos derivados de quinolina y quinoxalina, composicion farmaceutica, combinacion farmaceutica; kit farmaceutico; y su uso para tratar aterosclerosis, enfermedad de arteria coronaria, enfermedad cardiaca coronaria, enfermedad vascular coronaria, | |
EP1742643A4 (en) | MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION | |
WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
BRPI0607003A2 (pt) | forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda | |
GT200600109A (es) | Derivados de acido pirimidincarboxilico y su uso | |
NO20091182L (no) | 2-fenoksypyrimidinonanaloger | |
ATE510536T1 (de) | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen | |
WO2007070355A3 (en) | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes | |
BRPI0607976A2 (pt) | composição farmacêutica e uso de uma composição | |
EA200702534A1 (ru) | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2) | |
Emini Veseli | Search for new therapeutic options to prevent and treat plaque neovascularization and atherogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |